| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1274 | 2016 |
| Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ... Journal of Clinical Oncology 37 (9), 693-702, 2019 | 360 | 2019 |
| Current landscape of immunotherapy in breast cancer: a review S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ... JAMA oncology 5 (8), 1205-1214, 2019 | 324 | 2019 |
| A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors SP Patel, M Othus, YK Chae, FJ Giles, DE Hansel, PP Singh, A Fontaine, ... Clinical Cancer Research 26 (10), 2290-2296, 2020 | 264 | 2020 |
| Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression R Hassan, AC Miller, E Sharon, A Thomas, JC Reynolds, A Ling, ... Science translational medicine 5 (208), 208ra147-208ra147, 2013 | 262 | 2013 |
| Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers R Hassan, SJ Cohen, M Phillips, I Pastan, E Sharon, RJ Kelly, ... Clinical cancer research 16 (24), 6132-6138, 2010 | 236 | 2010 |
| Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma SP Patel, M Othus, Y Chen, GP Wright Jr, KJ Yost, JR Hyngstrom, ... New England Journal of Medicine 388 (9), 813-823, 2023 | 232 | 2023 |
| IGF-1R as an anti-cancer target—trials and tribulations HX Chen, E Sharon Chinese journal of cancer 32 (5), 242, 2013 | 232 | 2013 |
| Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B … PA Brown, L Ji, X Xu, M Devidas, LE Hogan, MJ Borowitz, EA Raetz, ... Jama 325 (9), 833-842, 2021 | 230 | 2021 |
| Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study MS Khodadoust, AH Rook, P Porcu, F Foss, AJ Moskowitz, A Shustov, ... Journal of Clinical Oncology 38 (1), 20, 2020 | 193 | 2020 |
| Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study TS Uldrick, PH Gonçalves, M Abdul-Hay, AJ Claeys, B Emu, MS Ernstoff, ... JAMA oncology 5 (9), 1332-1339, 2019 | 186 | 2019 |
| Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor … R Hassan, E Sharon, A Thomas, J Zhang, A Ling, M Miettinen, ... Cancer 120 (21), 3311-3319, 2014 | 184 | 2014 |
| Tuberculosis following PD-1 blockade for cancer immunotherapy DL Barber, S Sakai, RR Kudchadkar, SP Fling, TA Day, JA Vergara, ... Science translational medicine 11 (475), eaat2702, 2019 | 169 | 2019 |
| Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome BP Geisler, RA Raad, D Esaian, E Sharon, DR Schwartz Journal for immunotherapy of cancer 3, 1-4, 2015 | 155 | 2015 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576, 2020 | 151 | 2020 |
| Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce HM Kluger, HA Tawbi, ML Ascierto, M Bowden, MK Callahan, E Cha, ... Journal for immunotherapy of cancer 8 (1), 2020 | 150 | 2020 |
| Immune checkpoint inhibitors in clinical trials E Sharon, H Streicher, P Goncalves, HX Chen Chinese journal of cancer 33 (9), 434, 2014 | 138 | 2014 |
| Immuno-oncology trial endpoints: capturing clinically meaningful activity V Anagnostou, M Yarchoan, AR Hansen, H Wang, F Verde, E Sharon, ... Clinical Cancer Research 23 (17), 4959-4969, 2017 | 137 | 2017 |
| Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD (L)-1 … JD Schoenfeld, A Giobbie-Hurder, S Ranasinghe, KZ Kao, A Lako, J Tsuji, ... The Lancet Oncology 23 (2), 279-291, 2022 | 132 | 2022 |
| Nivolumab is effective in mismatch repair–deficient noncolorectal cancers: Results from arm Z1D—A subprotocol of the NCI-MATCH (EAY131) study NS Azad, RJ Gray, MJ Overman, JD Schoenfeld, EP Mitchell, JA Zwiebel, ... Journal of Clinical Oncology 38 (3), 214, 2020 | 132 | 2020 |
